Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Launched by AZIENDA OSPEDALIERA OSPEDALE INFANTILE REGINA MARGHERITA SANT'ANNA · Nov 3, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a type of cancer called sarcomas, specifically looking at how the genetics of these tumors can help doctors provide better treatments for children, adolescents, and young adults. Sarcomas are tumors that arise from connective tissues, and they can be quite challenging to treat, especially when they come back after treatment. By analyzing the genetic makeup of these tumors using advanced techniques, researchers hope to find new ways to understand how these cancers develop and to tailor treatments to each patient's unique situation.

To be eligible for this trial, participants should be 24 years old or younger and have a confirmed diagnosis of certain types of sarcomas, such as Osteosarcoma, Ewing Sarcoma, or Synovial Sarcoma. It’s important that patients or their guardians provide written consent for the study, which includes allowing the collection of a tumor sample and a blood sample. If you decide to participate, you can expect to have your tumor's genetic profile analyzed, which may help guide future treatment options. This trial is currently recruiting participants, so it's a great opportunity for those affected by these types of cancer to contribute to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis.
• • 2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma
• • 3. Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample.
• • 4. Patients aged ≤24 years
• • 5. Pathological review of tumor samples.
• • 6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional.
• Exclusion Criteria:
• • 1. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.